151 related articles for article (PubMed ID: 31786895)
1. Different subtypes of metaplastic breast cancer might have different sensitivity to neoadjuvant chemotherapy.
Altundag K
J BUON; 2019; 24(5):2205. PubMed ID: 31786895
[No Abstract] [Full Text] [Related]
2. [Practice and consideration on neoadjuvant therapy for early breast cancer].
Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):555-7. PubMed ID: 21029704
[No Abstract] [Full Text] [Related]
3. High-dose chemotherapy for triple negative breast cancer.
De Giorgi U; Rosti G; Frassineti L; Kopf B; Giovannini N; Zumaglini F; Marangolo M
Ann Oncol; 2007 Jan; 18(1):202-203. PubMed ID: 16971660
[No Abstract] [Full Text] [Related]
4. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
Mehta RS
J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
[No Abstract] [Full Text] [Related]
5. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
6. Re: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Panasci LC
J Clin Oncol; 2009 Sep; 27(26):e111; author reply e112-3. PubMed ID: 19667259
[No Abstract] [Full Text] [Related]
7. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.
Yang L; Zhong X; Pu T; Qiu Y; Ye F; Bu H
World J Surg Oncol; 2018 Mar; 16(1):51. PubMed ID: 29514654
[TBL] [Abstract][Full Text] [Related]
10. Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.
Ottestad L; Fronth L; Rajendiran S; Hege Aksnes L; Eikesdal HP; Støre Blix E; Ewertz M
Acta Oncol; 2019 Mar; 58(3):385-387. PubMed ID: 30798641
[No Abstract] [Full Text] [Related]
11. Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
Bilgin B; Şendur MA; Hızal M; Akıncı MB; Dede DŞ; Yalçın B
Future Oncol; 2019 Jan; 15(2):105-107. PubMed ID: 30484708
[No Abstract] [Full Text] [Related]
12. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
14. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
15. [Molecular subtypes and individualized treatment of breast cancer].
Xu BH; Zhang P
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):641-4. PubMed ID: 21122374
[No Abstract] [Full Text] [Related]
16. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
19. Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.
Wang LC; Wang LS; Li AX; Shi ZZ; Li YQ; Huang W; Chen SM; Han F; Zhu DQ
Technol Cancer Res Treat; 2020; 19():1533033820928435. PubMed ID: 32508292
[TBL] [Abstract][Full Text] [Related]
20. Receptor discordances after neoadjuvant chemotherapy and their effects on survival.
Tural D; Karaca M; Zirtiloglu A; M Hacioglu B; Sendur MA; Ozet A
J BUON; 2019; 24(1):20-25. PubMed ID: 30941947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]